ABBOTT LABORATORIES Aktie

 

Moreland, Mary K. - Vorstand - Tag der Transaktion: 2026-11-05...

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer....

NORTH CHICAGO (dpa-AFX) - Monday, Abbott Laboratories (ABT) announced one-year results for its investigational Amulet 360 Left Atrial Appendage Occluder from the VERITAS study, evaluating the safe......

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

Abbott Laboratories' outlook is looking brighter after a recent development....

NORTH CHICAGO (dpa-AFX) - Monday, Abbott Laboratories (ABT), a global healthcare company, announced the commercial availability of its next-generation Oncodetect molecular residual disease (MRD) t......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Abbott's $7.4B free cash flow and 0.3x debt load contrast sharply with UnitedHealth's $16.1B free cash flow but higher leverage and government policy risk....

Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Abbott's Q3 earnings miss weighs on its stock despite double-digit revenue growth and expanding margins, while lower 2026 sales guidance raises concerns....

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

Abbott (ABT) delivered earnings and revenue surprises of -0.70% and +0.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...

ABBOTT PARK (dpa-AFX) - Der Pharmakonzern Abbott (Abbott Laboratories) will sein Ernährungsgeschäft in ein eigenständiges und börsennotiertes Unternehmen ausgliedern. Die Abspaltung solle bis Ende 2027 abgeschlossen ......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Gesundheitssektor - Der US-Medizintechnikkonzern Abbott Laboratories will sein Geschäft mit klinischer Ernährung und Babynahrung ‌abspalten....

NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced intention to separate Nutrition business into an independent, publicly traded company. Daniel Salvadori, executive vice president and group preside......

NORTH CHICAGO (dpa-AFX) - While reporting financial results for the third quarter on Wednesday, healthcare company Abbott Laboratories (ABT) provided adjusted earnings guidance for the fourth quar......

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) announced earnings for third quarter that Drops, from the same period last yearThe company's earnings came in at $920 million, or $0.53 per shar......

Abbott Laboratories said it plans to spin off its embattled nutrition unit into a separate company....